RT Journal Article
SR Electronic
T1 Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.28.20163626
DO 10.1101/2020.07.28.20163626
A1 Nikhil Shri Sahajpal
A1 Ashis K Mondal
A1 Allan Njau
A1 Sudha Ananth
A1 Arvind Kothandaraman
A1 Madhuri Hegde
A1 Alka Chaubey
A1 Sandeep Padala
A1 Vamsi Kota
A1 Kevin Caspary
A1 Stephen M Tompkins
A1 Ted Ross
A1 Amyn M. Rojani
A1 Ravindra Kolhe
YR 2020
UL http://medrxiv.org/content/early/2020/07/30/2020.07.28.20163626.abstract
AB The current gold-standard molecular diagnosis for COVID-19 is based on a multi-step assay involving RNA-extraction and RT-PCR analysis for the detection of SARS-CoV-2. RNA-extraction step has been a major rate-limiting step in implementing high-throughput screening for COVID-19 during this pandemic. Moreover, clinical laboratories are facing several challenges that include cost, reagents, instrumentation, turn-around time, trained personnel, and supply-chain constraints to efficiently implement and sustain testing. Cognizant of these limitations, we evaluated the extraction-free methods described in the literature and have developed an innovative, simplified and easy protocol employing limited reagents to extract RNA for subsequent RT-PCR analysis. Nasopharyngeal-swab samples were subjected to the following individual conditions: 65°C for 15 minutes; 80°C for 5 minutes; 90°C for 5 minutes or 80°C for 1 minute, and processed for direct RT-PCR. These groups were also compared with a supplemental protocol adding isopropanol-ethanol-water elution steps followed by RT-PCR assay. The direct RT-PCR assay did not detect SARS-CoV-2 within the various temperature incubation only groups, whereas, the 90°C for 5 minutes-isopropanol-ethanol-water method was found to be comparable to the FDA-EUA method. Evaluation of the performance metrics for 100 clinical samples demonstrated a sensitivity of 94.2% and a specificity of 100%. The limit of detection was ascertained to be ∼40 copies/ml by absolute-quantification. The protocol presented for this assay employs limited reagents and yields results with high sensitivity. Additionally, it presents a simplified methodology that would be easier to implement in laboratories in limited resource countries in order to meet the high current COVID-19 testing needs.Competing Interest StatementRK has received honoraria, travel funding, and research support from Illumina, Asuragen, QIAGEN, and BMS. MH, AK and AC holds stock options at PerkinElmer Inc.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:AU IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data asscoaited with the manuscript is avaliable.